Developer docs
API playgroundTry for free, no card

Search company profiles

Verona Pharma

Full company profile

uuid0000rga

Namestring
Verona Pharma
Legal namestring
Verona Pharma plc
Company typeenum
Private
Founded yearint
2005
Descriptiontext

Verona Pharma is a UK-based clinical-stage and now commercial-stage biopharmaceutical company founded in 2005, focused on developing and commercializing novel therapeutics for chronic respiratory diseases. The company's lead and only commercial product is Ohtuvayre (ensifentrine), a first-in-class, selective dual inhibitor of phosphodiesterase 3 and 4 (PDE3/PDE4) delivered via standard jet nebulizer. The mechanism combines bronchodilation (PDE3 inhibition) with anti-inflammatory activity (PDE4 inhibition) in a single inhaled molecule, addressing a long-standing unmet need in chronic obstructive pulmonary disease (COPD) patients who remain symptomatic despite existing maintenance therapy. Ohtuvayre received FDA approval in June 2024 for maintenance treatment of COPD in adult patients, making it the first novel mechanism approved for COPD maintenance in over two decades.\n\nThe company served respiratory specialists, pulmonologists, and the large U.S. COPD patient population through a focused, direct specialty sales force in the United States, with international expansion pursued via licensing partnerships — most notably the 2021 Nuance Pharma agreement covering Greater China, which yielded Hong Kong approval in March 2026. Verona Pharma's revenue mechanics are entirely driven by U.S. net product sales of Ohtuvayre through wholesale and specialty pharmacy distribution channels, with Q1 2025 net product sales of $71 million and equity-research-projected peak revenue in the $1-4 billion range.\n\nThe company had been publicly listed on NASDAQ (ticker: VRNA) and the London Stock Exchange (ticker: VRP) with a headcount of 101-250 employees prior to its acquisition by Merck & Co. for approximately $10 billion, effective October 7, 2025. Under Merck ownership, Verona Pharma operates as a subsidiary within Merck's respiratory franchise, with geographic operations spanning the United Kingdom, the United States, Ireland, and selected Asia-Pacific markets via partner Nuance Pharma. Two material debt facilities were raised during the standalone era: $150 million in October 2022 to extend runway ahead of NDA submission, and $400 million in January 2024 to fund commercial launch and U.S. sales infrastructure.

Short descriptiontext

Verona Pharma is a UK-based biopharmaceutical company that developed Ohtuvayre (ensifentrine), a first-in-class dual PDE3/PDE4 inhibitor approved by the FDA in June 2024 for COPD maintenance treatment. It was acquired by Merck & Co. for approximately $10 billion in October 2025.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
respiratory pharmaceuticals, COPD treatment, inhaled therapeutics, PDE inhibitors, biopharmaceutical products
Industry3 codes
PRIMARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAKANAD
Asthma & Allergy-Related Pulmonary Care
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Respiratory Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Ohtuvayre (ensifentrine) Sales
TypeOne Time License
Description

Revenue generated from sales of FDA-approved COPD maintenance treatment Ohtuvayre (ensifentrine). The drug achieved $71 million in Q1 2025 sales prior to the Merck acquisition and is projected to reach $1-4 billion in peak annual revenue.

pharmaphorum.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Ohtuvayre
Description

Ohtuvayre (ensifentrine) is an FDA-approved respiratory treatment for COPD maintenance therapy. It is the first novel inhaled mechanism for COPD treatment in over 20 years, combining bronchodilator and non-steroidal anti-inflammatory effects in a single molecule that inhibits both phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4).

veronapharma.com
+1 more record
Core offering1 text field

Verona Pharma develops and commercializes Ohtuvayre (ensifentrine), an FDA-approved inhaled dual PDE3/PDE4 inhibitor for maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. The product is the first novel inhaled mechanism for COPD in over 20 years, combining bronchodilator and non-steroidal anti-inflammatory effects in a single molecule. Following FDA approval in June 2024, the company built dedicated US commercial infrastructure and was subsequently acquired by Merck & Co. for approximately $10 billion in October 2025.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Ohtuvayre achieved $71 million in Q1 2025 sales
+2 more records
Product overview1 text field

Verona Pharma is a biopharmaceutical company focused on developing novel respiratory treatments. The company's portfolio centers on a single product, Ohtuvayre (ensifentrine), a first-in-class dual PDE3 and PDE4 inhibitor delivered via inhalation for COPD treatment. The technology platform enables bronchodilator and anti-inflammatory effects from a single molecule. Verona Pharma operates as a subsidiary of Merck & Co., Inc. following acquisition in October 2025.

Product and service1 record
1Ohtuvayre (ensifentrine)
CategoryRespiratory Pharmaceuticals / COPD Maintenance Therapy
Description

FDA-approved inhaled maintenance therapy for the treatment of chronic obstructive pulmonary disease (COPD) in adult patients. Ohtuvayre is a first-in-class dual PDE3 and PDE4 inhibitor that combines bronchodilator and non-steroidal anti-inflammatory effects in a single molecule, providing a novel mechanism of action not seen in COPD treatment for over 20 years. It is indicated for adult patients requiring maintenance therapy and is distributed through US pharmaceutical channels.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-01-01
Description

Nuance Pharma holds a licensing agreement with Verona Pharma for Ohtuvayre (ensifentrine) in Greater China. Under this 2021 licensing agreement, Nuance Pharma received rights to develop and commercialize Ohtuvayre for COPD in Hong Kong, Macau, and China. The Hong Kong Drug Office approved Ohtuvayre in March 2026 under the '1+ mechanism' as the second regulatory approval outside the US.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Viatris markets generic and branded respiratory products including Yupelri and other inhaled COPD therapies, serving as a broad incumbent in the respiratory pharmaceutical space with significant distribution scale.

TypeDirect peer
Description

GSK markets Trelegy Ellipta and Anoro Ellipta for COPD maintenance therapy, directly competing with Ohtuvayre in the same prescriber base and patient population. GSK is the established market leader in inhaled respiratory combinations.

TypeDirect peer
Description

AstraZeneca markets Breztri Aerosphere and other inhaled COPD/respiratory therapies, competing head-to-head with Ohtuvayre in maintenance treatment. AZ is a top-tier respiratory player with deep pulmonology relationships.

4Boehringer Ingelheim
TypeDirect peer
Description

Boehringer Ingelheim markets Spiriva, Stiolto Respimat, and other leading COPD therapies, directly competing with Ohtuvayre in the long-acting bronchodilator market. BI is one of the largest respiratory pharma companies globally.

TypeEmerging player
Description

Theravance Biopharma develops and commercializes respiratory therapies including Yupelri (revefenacin), competing in the COPD maintenance space with a focus on nebulized and inhaled delivery.

TypeEmerging player
Description

Insmed is developing brensocatib for bronchiectasis and has pipeline programs in respiratory disease, with overlapping R&D focus in chronic pulmonary conditions relevant to Verona's specialty pharma positioning.

TypeBroad incumbent
Description

Chiesi markets Foster (beclomethasone/formoterol) and other respiratory products globally, making it a broad incumbent in the inhaled respiratory market with overlapping therapeutic focus on COPD and asthma.

TypeEmerging player
Description

Tarsus Pharmaceuticals commercializes Xdemvy for demodex blepharitis and has an emerging respiratory pipeline with mechanistic adjacency to Verona's specialty pharma respiratory focus.

TypeBroad incumbent
Description

United Therapeutics markets Tyvaso and other inhaled treprostinil products for pulmonary hypertension and PAH, operating in adjacent inhaled respiratory therapeutics with specialty pharma distribution.

TypeBroad incumbent
Description

Novartis has a respiratory portfolio including Ultibro and Seebri for COPD, and remains a broad incumbent with overlapping therapeutic categories though its respiratory focus has diminished post-Sandoz strategy.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors29 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Verona Pharma

Respiratory Pharmaceuticalsveronapharma.com

Verona Pharma is a UK-based biopharmaceutical company that developed Ohtuvayre (ensifentrine), a first-in-class dual PDE3/PDE4 inhibitor approved by the FDA in June 2024 for COPD maintenance treatment. It was acquired by Merck & Co. for approximately $10 billion in October 2025.

What Verona Pharma does

Verona Pharma is a UK-based clinical-stage and now commercial-stage biopharmaceutical company founded in 2005, focused on developing and commercializing novel therapeutics for chronic respiratory diseases. The company's lead and only commercial product is Ohtuvayre (ensifentrine), a first-in-class, selective dual inhibitor of phosphodiesterase 3 and 4 (PDE3/PDE4) delivered via standard jet nebulizer. The mechanism combines bronchodilation (PDE3 inhibition) with anti-inflammatory activity (PDE4 inhibition) in a single inhaled molecule, addressing a long-standing unmet need in chronic obstructive pulmonary disease (COPD) patients who remain symptomatic despite existing maintenance therapy. Ohtuvayre received FDA approval in June 2024 for maintenance treatment of COPD in adult patients, making it the first novel mechanism approved for COPD maintenance in over two decades.\n\nThe company served respiratory specialists, pulmonologists, and the large U.S. COPD patient population through a focused, direct specialty sales force in the United States, with international expansion pursued via licensing partnerships — most notably the 2021 Nuance Pharma agreement covering Greater China, which yielded Hong Kong approval in March 2026. Verona Pharma's revenue mechanics are entirely driven by U.S. net product sales of Ohtuvayre through wholesale and specialty pharmacy distribution channels, with Q1 2025 net product sales of $71 million and equity-research-projected peak revenue in the $1-4 billion range.\n\nThe company had been publicly listed on NASDAQ (ticker: VRNA) and the London Stock Exchange (ticker: VRP) with a headcount of 101-250 employees prior to its acquisition by Merck & Co. for approximately $10 billion, effective October 7, 2025. Under Merck ownership, Verona Pharma operates as a subsidiary within Merck's respiratory franchise, with geographic operations spanning the United Kingdom, the United States, Ireland, and selected Asia-Pacific markets via partner Nuance Pharma. Two material debt facilities were raised during the standalone era: $150 million in October 2022 to extend runway ahead of NDA submission, and $400 million in January 2024 to fund commercial launch and U.S. sales infrastructure.

Verona Pharma firmographics

Firmographics
Name
Verona Pharma
Legal name
Verona Pharma plc
Website
https://veronapharma.com
Company type
Private
Founded year
2005
Operating status
Acquired
Headcount range
101–250 employees
Short description
Verona Pharma is a UK-based biopharmaceutical company that developed Ohtuvayre (ensifentrine), a first-in-class dual PDE3/PDE4 inhibitor approved by the FDA in June 2024 for COPD maintenance treatment. It was acquired by Merck & Co. for approximately $10 billion in October 2025.
Ownership category
akta.pro rank

Verona Pharma industry classification

Industry
Product category
Respiratory Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAIAAAH
Respiratory & Allergy Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAKANAD
Asthma & Allergy-Related Pulmonary Care

Keywords

  • Respiratory pharmaceuticals
  • COPD treatment
  • Inhaled therapeutics
  • PDE inhibitors
  • Biopharmaceutical products

Where Verona Pharma is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Verona Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. Ohtuvayre (ensifentrine) Sales: Revenue generated from sales of FDA-approved COPD maintenance treatment Ohtuvayre (ensifentrine). The drug achieved $71 million in Q1 2025 sales prior to the Merck acquisition and is projected to reach $1-4 billion in peak annual revenue.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Verona Pharma product offering

Product offering

Core offering

Verona Pharma develops and commercializes Ohtuvayre (ensifentrine), an FDA-approved inhaled dual PDE3/PDE4 inhibitor for maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. The product is the first novel inhaled mechanism for COPD in over 20 years, combining bronchodilator and non-steroidal anti-inflammatory effects in a single molecule. Following FDA approval in June 2024, the company built dedicated US commercial infrastructure and was subsequently acquired by Merck & Co. for approximately $10 billion in October 2025.

Product overview

Verona Pharma is a biopharmaceutical company focused on developing novel respiratory treatments. The company's portfolio centers on a single product, Ohtuvayre (ensifentrine), a first-in-class dual PDE3 and PDE4 inhibitor delivered via inhalation for COPD treatment. The technology platform enables bronchodilator and anti-inflammatory effects from a single molecule. Verona Pharma operates as a subsidiary of Merck & Co., Inc. following acquisition in October 2025.

Differentiator

Problem solved

Functional benefit

Brands

  • Ohtuvayre: Ohtuvayre (ensifentrine) is an FDA-approved respiratory treatment for COPD maintenance therapy. It is the first novel inhaled mechanism for COPD treatment in over 20 years, combining bronchodilator and non-steroidal anti-inflammatory effects in a single molecule that inhibits both phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4).
  • Ensifentrine

Products and services

  • Ohtuvayre (ensifentrine) FDA-approved inhaled maintenance therapy for the treatment of chronic obstructive pulmonary disease (COPD) in adult patients. Ohtuvayre is a first-in-class dual PDE3 and PDE4 inhibitor that combines bronchodilator and non-steroidal anti-inflammatory effects in a single molecule, providing a novel mechanism of action not seen in COPD treatment for over 20 years. It is indicated for adult patients requiring maintenance therapy and is distributed through US pharmaceutical channels.

Quantifiable outcome

  • Ohtuvayre achieved $71 million in Q1 2025 sales
  • +2 more outcomes

Companies that use Verona Pharma

Customer profile

Segments2 records

Ideal customer profiles2 records

Verona Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Verona Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Nuance PharmamajorOEM/ Whitelabel/ Licensing Partner · 1 January 2021Nuance Pharma holds a licensing agreement with Verona Pharma for Ohtuvayre (ensifentrine) in Greater China. Under this 2021 licensing agreement, Nuance Pharma received rights to develop and commercialize Ohtuvayre for COPD in Hong Kong, Macau, and China. The Hong Kong Drug Office approved Ohtuvayre in March 2026 under the '1+ mechanism' as the second regulatory approval outside the US.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Verona Pharma competitors and assessment

Company assessment

Broad incumbents

  • Viatris: Viatris markets generic and branded respiratory products including Yupelri and other inhaled COPD therapies, serving as a broad incumbent in the respiratory pharmaceutical space with significant distribution scale.
  • Chiesi Farmaceutici: Chiesi markets Foster (beclomethasone/formoterol) and other respiratory products globally, making it a broad incumbent in the inhaled respiratory market with overlapping therapeutic focus on COPD and asthma.
  • United Therapeutics: United Therapeutics markets Tyvaso and other inhaled treprostinil products for pulmonary hypertension and PAH, operating in adjacent inhaled respiratory therapeutics with specialty pharma distribution.
  • Novartis: Novartis has a respiratory portfolio including Ultibro and Seebri for COPD, and remains a broad incumbent with overlapping therapeutic categories though its respiratory focus has diminished post-Sandoz strategy.

Direct peers

  • GlaxoSmithKline: GSK markets Trelegy Ellipta and Anoro Ellipta for COPD maintenance therapy, directly competing with Ohtuvayre in the same prescriber base and patient population. GSK is the established market leader in inhaled respiratory combinations.
  • AstraZeneca: AstraZeneca markets Breztri Aerosphere and other inhaled COPD/respiratory therapies, competing head-to-head with Ohtuvayre in maintenance treatment. AZ is a top-tier respiratory player with deep pulmonology relationships.
  • Boehringer Ingelheim: Boehringer Ingelheim markets Spiriva, Stiolto Respimat, and other leading COPD therapies, directly competing with Ohtuvayre in the long-acting bronchodilator market. BI is one of the largest respiratory pharma companies globally.

Emerging players

  • Theravance Biopharma: Theravance Biopharma develops and commercializes respiratory therapies including Yupelri (revefenacin), competing in the COPD maintenance space with a focus on nebulized and inhaled delivery.
  • Insmed: Insmed is developing brensocatib for bronchiectasis and has pipeline programs in respiratory disease, with overlapping R&D focus in chronic pulmonary conditions relevant to Verona's specialty pharma positioning.
  • Tarsus Pharmaceuticals: Tarsus Pharmaceuticals commercializes Xdemvy for demodex blepharitis and has an emerging respiratory pipeline with mechanistic adjacency to Verona's specialty pharma respiratory focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Verona Pharma social profiles

Digital presence

Verona Pharma compliance and trust

Trust signal

Compliance1 record

Verona Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Verona Pharma leadership team

Management profile

Number of profiles

Profiles5 records

Verona Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Verona Pharma funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors29 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Verona Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Verona Pharma

What does Verona Pharma do?

Verona Pharma develops and commercializes Ohtuvayre (ensifentrine), an FDA-approved inhaled dual PDE3/PDE4 inhibitor for maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. The product is the first novel inhaled mechanism for COPD in over 20 years, combining bronchodilator and non-steroidal anti-inflammatory effects in a single molecule. Following FDA approval in June 2024, the company built dedicated US commercial infrastructure and was subsequently acquired by Merck & Co. for approximately $10 billion in October 2025.

Is Verona Pharma a public or private company?

Verona Pharma is a private company. It is classified as corporate owned and is currently acquired.

When was Verona Pharma founded?

Verona Pharma was founded in 2005. It employs 101 to 250 people.

Where is Verona Pharma based?

Verona Pharma is headquartered in London, United Kingdom, in the Europe region.

How does Verona Pharma make money?

One revenue line is on record: ohtuvayre (ensifentrine) Sales.

Who are Verona Pharma's main competitors?

Broad incumbents on record are Viatris, Chiesi Farmaceutici, United Therapeutics and Novartis. Direct peers are GlaxoSmithKline, AstraZeneca and Boehringer Ingelheim. Emerging players are Theravance Biopharma, Insmed and Tarsus Pharmaceuticals.

Does Verona Pharma have an API?

No public API is recorded for Verona Pharma.

What industry is Verona Pharma in?

Verona Pharma's product category is Respiratory Pharmaceuticals. Its primary akta.pro industry code is HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals, with a secondary code of HLAIAAAH, Respiratory & Allergy Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Frazier Life Sciences Raises More Than $1.1 Billion For Public Biotech Fund, Bringing Commitments To $2.8 BillionFrazier Life Sciences raised over $1.1 billion in new commitments for its public biotech fund, bringing total committed capital to about $2.8 billion. The fund targets small- and mid-cap public biotech companies, with Verona Pharma and Alpine Immune Sciences among its largest historical holdings.BioSpaceFrazier adds $1.1B+ to small and mid-sized biotech fundFrazier Life Sciences raised over $1.1 billion in new commitments for its public small- and mid-cap biotech fund, bringing total capital to roughly $2.8 billion. The fund has backed companies like Verona Pharma and Alpine Immune Sciences, which were acquired for $10 billion and $4.9 billion respectively.Business Wire BlogFrazier Life Sciences Adds Over $1.1 Billion to Frazier Life Sciences Public FundFrazier Life Sciences closed over $1.1 billion in capital commitments to its Public Fund, bringing total committed capital to approximately $2.8 billion. The fund, launched in 2021, targets small- and mid-cap public biotech companies and has acquired Verona Pharma and Alpine Immune Sciences.Labiotech.euMerck after Keytruda: what the pipeline looks likeMerck & Co. is executing a multi-billion-dollar acquisition strategy to prepare for the Keytruda patent cliff, with U.S. patents expiring from 2028 and the drug currently generating $31.7 billion in annual sales, nearly half the company's total revenue. The company completed approximately $26 billion in acquisitions between October 2025 and March 2026—Verona Pharma ($10B), Cidara Therapeutics ($9.2B), and Terns Pharmaceuticals ($6.7B)—to build new growth pillars in cardio-pulmonary medicine, immunology, and infectious disease alongside its expanding oncology business.European BiotechnologyAZ buys ex-China rights to Sino’s COPD drug for $2.1bnAstraZeneca agreed to pay $200 million upfront plus $1.9 billion for the PDE 3/4 inhibitor TQC3721, a late-stage Chinese COPD asset. The deal includes tiered royalties and could give AZ a competitor to MSD's Ohtuvayre, which generated over $500 million in 2025 sales.BioSpacePharmaceutical Market Size to Exceed USD 3.20 Trillion by 2035, Driven by Rising Chronic Disease Burden and Expanding Biopharmaceutical InnovationPrecedence Research released its 2025 pharmaceutical market report projecting global market size to grow from USD 1.77 trillion in 2025 to USD 3.20 trillion by 2035, representing a CAGR of 6.10%, driven by rising chronic disease prevalence, aging populations, increasing healthcare expenditure, and advancements in biologics and precision medicine. North America held the largest regional share at 42% in 2025, while Asia Pacific is forecast to be the fastest-growing region through 2035. Recent notable corporate developments include Merck's October 2025 completion of its approximately US$10 billion acquisition of Verona Pharma, Eli Lilly's US$4.5 billion manufacturing investment announced in May 2026, and Sun Pharmaceutical's ₹3,000 crore greenfield facility investment in Madhya Pradesh announced in December 2025.CapitalИзтичането на патенти ускори сделките във фармациятаPatent expirations and improved market conditions drove M&A activity in the pharmaceutical sector in 2025. Johnson & Johnson acquired Intra-Cellular Therapies for $14.6 billion, Novartis bought Avidity Biosciences for $12 billion, and Pfizer outbid Metsera for $10 billion. The deals reflect a renewed wave of acquisitions following a period of uncertainty.Labiotech.euSurge in M&As driven by patent expirationsM&A activity in healthcare and life sciences surged, with EY reporting an 81% jump in investments to $240 billion last year. Analysts attribute the spike to patent cliffs, as big pharma acquire biotechs to replace revenue from expiring blockbusters. Pfizer's $10 billion Metsera deal and Merck's Keytruda patent expiration are cited as examples.The Motley Fool3 Dividend Stocks to Hold for the Next 10 YearsThe article recommends Merck, Verizon, and Equinix as dividend stocks to hold for the next decade. Merck's Keytruda patent expires in 2028, but its pipeline could generate $70 billion in annual revenue. Verizon and Equinix offer stable income, with Verizon's dividend raised for 19 years and Equinix's for 11.